Abstract
Objectives To analyze the literature data and research status of immunotherapy for the treatment of diffuse large B-cell lymphoma since the establishment of the Web of Science (WOS) core database. Material and Methods The WOS core database was searched for literature related to immunotherapy for diffuse large B-cell lymphoma, and the included literature was formatted, cleaned, node merged, and analyzed using CiteSpace software. Based on the parameters set, the included literature was analyzed for trends in publications, author publications and inter-author collaborations, national publications, global institutional publications and inter-institutional collaborations, citations, keyword co-occurrence, keyword emergence, and keyword clustering. The final visual knowledge map was created. Results A total of 370 articles were selected for inclusion. The highest number of annual publications was in 2021. Four individuals, Marconato Laura; Ansell, Stephen M; Xiao Min; and Aresu Luca, were the most published scholars. The United States with 152 publications was the country with the highest number of publications. Benjamin J is the most cited scholar in this field. The top three most cited keywords were “expression,” “diffuse large b-cell lymphoma,” and “rituximab.” “Bone marrow transplantation” was the first and longest-running keyword. “Cancer immunotherapy,” “resistance,” and “cytokine release syndrome” are still hot topics. The keyword clusters “pd-l1,” “antibody-based,” “immunotherapy,” and “cd19” were the main clusters studied. Conclusion After visualization and analysis, the recent research and hot trends in the field of immunotherapy for diffuse large B-cell lymphoma were reviewed using knowledge mapping and further presented in a visualized form, providing a reference for further development of related research in the future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.